Roth MKM lowered the firm’s price target on ProSomnus to $6 from $9 but keeps a Buy rating on the shares. The analyst cites the increased expected dilution given the company’s capital needs but notes that its Q2 results were better than expected while the management also boosted its revenue growth target for 2023 to 40% from 35%.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on OSA:
- ProSomnus Reports Record Second Quarter 2023 Top-Line Financial Results
- ProSomnus reports Q2 adjusted EPS (1c) vs. (71c) last year
- ProSomnus plans to design head-to-head clinical trial of OAT vs. HNS
- ProSomnus Announces Second Quarter 2023 Investor Call and Business Update
- ProSomnus announces results of snoring survey